Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13135700 | 0.92 | — | — | |
| SCHEMBL23655909 | 0.83 | ELANE (0.30) | — | |
| SCHEMBL25919081 | 0.81 | — | — | |
| SCHEMBL17199405 | 0.78 | CYP1A2 (0.31) | CYP1A2POLBGAA | |
| SCHEMBL20749862 | 0.78 | CYP1A2 (0.31) | CYP1A2POLBGAA | |
| SCHEMBL2666674 | 0.78 | — | — | |
| SCHEMBL2667326 | 0.78 | — | — | |
| SCHEMBL1106858 | 0.71 | — | — | |
| SCHEMBL21335986 | 0.71 | — | — | |
| SCHEMBL13925987 | 0.71 | KDM4E (0.39) | CYP1A2POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4281461-B1 | METHOD FOR PREPARING AN ENANTIOMERICALLY ENRICHED FORM OF 3-(2-CHLOROTHIAZOL-5-YL)-8-METHYL-7-OXO-6-PHENYL-2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM-5-OLATE | BASF SE (DE) | 2026-01-21 | — | — | EP | claimed |
| CN-117940504-A | Triazole containing polymers and methods of use thereof | 威廉马什莱斯大学 | 2024-04-26 | — | — | CN | disclosed |
| US-9115095-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140350241-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS LLC | 2014-11-27 | — | — | US | disclosed |
| EP-2803658-A1 | Phosphinate ruthenium complexes | IDENIX Pharmaceuticals, Inc. (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8765966-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130267698-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS LLC | 2013-10-10 | — | — | US | disclosed |
| US-8481748-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130150572-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8410313-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20130030209-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309737-B2 | Phosphinate ruthenium complexes | IDENIX PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120041191-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | IDENIX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20100266539-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-7732442-B2 | Chemokine receptor antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7335791-B1 | Process for the synthesis of hydroxy aromatic acids | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-02-26 | — | — | US | disclosed |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150572-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, POP1 | CYP1A2 1489/4885POLB 282/4885GAA 4506/4885 |
| US-20140350241-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, POP1 | CYP1A2 1489/4885POLB 282/4885GAA 4506/4885 |
| US-20130267698-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, POP1 | CYP1A2 1489/4885POLB 282/4885GAA 4506/4885 |
| US-20120041191-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, PHOSPHO1 | CYP1A2 1864/4885POLB 230/4885GAA 4520/4885 |
| US-20100266539-A1 | CHEMOKINE RECEPTOR ANTAGONIST AND MEDICAL USE THEREOF | CCR5, CCR4, CCR1 | CYP1A2 1229/4885POLB 4287/4885GAA 3346/4885 |
| US-20130030209-A1 | PHOSPHINATE RUTHENIUM COMPLEXES | RPIA, NDUFS7, POP1 | CYP1A2 1489/4885POLB 282/4885GAA 4506/4885 |
| US-20070254886-A1 | Chemokine Receptor Antagonist and Medical Use Thereof | CCR5, CCR4, CCR1 | CYP1A2 1229/4885POLB 4287/4885GAA 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.